Related references
Note: Only part of the references are listed.Prognostic Significance of Immunophenotypic and Karyotypic Features of Philadelphia Positive B-Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors
Jesse Jaso et al.
CANCER (2011)
Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis
Simona Soverini et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final resullts of the CSTIBES02 trial
Josep-Maria Ribera et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Chemotherapy-Phased Imatinib Pulses Improve Long-Term Outcome of Adult Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Northern Italy Leukemia Group Protocol 09/00
Renato Bassan et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Donor-specific differences in long-term outcomes of myeloablative transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia
S. Lee et al.
LEUKEMIA (2010)
The Extent of Minimal Residual Disease Reduction After the First 4-Week Imatinib Therapy Determines Outcome of Allogeneic Stem Cell Transplantation in Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Seok Lee et al.
CANCER (2009)
Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study
B-S Cho et al.
LEUKEMIA (2009)
Harmonization of molecular monitoring of CML therapy in Europe
M. C. Mueller et al.
LEUKEMIA (2009)
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
Susan Branford et al.
BLOOD (2008)
Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy
Masamitsu Yanada et al.
HAEMATOLOGICA (2008)
Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: Antileukemic activity of chronic graft-versus-host disease
Seok Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
Heike Pfeifer et al.
BLOOD (2007)
Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia:: results of the GRAAPH-2003 study
Adrienne de Labarthe et al.
BLOOD (2007)
Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia
S. Branford et al.
LEUKEMIA (2006)
Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
Barbara Wassmann et al.
BLOOD (2006)
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors:: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Timothy Hughes et al.
BLOOD (2006)
High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia:: A phase II study by the Japan Adult Leukemia Study Group
M Yanada et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
S Lee et al.
BLOOD (2005)
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
DA Thomas et al.
BLOOD (2004)
Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia -: A Europe Against Cancer Program
J Gabert et al.
LEUKEMIA (2003)
Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia
S Lee et al.
BLOOD (2003)
Optimistic expectations and survival after hematopoietic stem cell transplantation
SJ Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2003)
Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse-transcription polymerase chain reaction
S Lee et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia -: results of the prospective multicenter LALA-94 trial
H Dombret et al.
BLOOD (2002)
Share Paper
